source
- Patient with EGFR-mutated NSCLC develops brain metastases after first-line EGFR inhibitor and chemotherapyDr. Sands presented a case of a patient with metastatic non-small cell lung cancer that carries an EGFR mutation. The patient was treated with a first-line regimen that combined an EGFR tyrosine k…
- Latus Bio raises $97 million to advance gene therapies for Huntington’s and Batten diseaseLatus Bio announced closing a $97 million Series A round, including a $43 million extension to a prior $54 million raise. Funding was led by 8VC and included eight other investors such as DCVC Bio…